Home World News Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood... World News Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 382 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research MOST POPULAR FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities December 1, 2020 Shelter Puppies Got A Private Tour Of The Georgia Aquarium March 31, 2020 A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in cHL August 25, 2020 ESMO Responds to Public Consultation on EU4Health Work Programme for 2027... June 15, 2026 Load more HOT NEWS How to Provide Support as a Long-Distance Cancer Caregiver Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib... Survey results reveal attitudes towards cancer screening during the pandemic FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer